Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M.

Am J Surg Pathol. 2011 Apr;35(4):608-14. doi: 10.1097/PAS.0b013e31820bcd2d.

PMID:
21383613
2.

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, Chen L, Magi-Galluzzi C, Zhou M.

Am J Surg Pathol. 2011 Jul;35(7):1062-8. doi: 10.1097/PAS.0b013e318215cc03.

PMID:
21623182
3.

The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.

Shah RB, Tadros Y, Brummell B, Zhou M.

Hum Pathol. 2013 May;44(5):786-94. doi: 10.1016/j.humpath.2012.06.024. Epub 2012 Nov 14.

PMID:
23158212
4.

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.

He H, Osunkoya AO, Carver P, Falzarano S, Klein E, Magi-Galluzzi C, Zhou M.

BJU Int. 2012 Dec;110(11 Pt B):E751-5. doi: 10.1111/j.1464-410X.2012.11557.x. Epub 2012 Oct 9.

5.

Clinicopathological features of prostate cancers detected after an initial diagnosis of 'atypical glands suspicious for cancer'.

Zhou M, Magi-Galluzzi C.

Pathology. 2010 Jun;42(4):334-8. doi: 10.3109/00313021003767280.

PMID:
20438405
6.

Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.

Zhou M, Shah R, Shen R, Rubin MA.

Am J Surg Pathol. 2003 Mar;27(3):365-71.

PMID:
12604893
7.

Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP.

Arch Pathol Lab Med. 2012 Aug;136(8):935-46. doi: 10.5858/arpa.2011-0424-OA.

8.

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.

Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA.

Am J Surg Pathol. 2002 Sep;26(9):1161-8.

PMID:
12218572
9.

Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.

Hum Pathol. 2004 Dec;35(12):1462-8.

PMID:
15619204
10.
11.
12.

Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.

Stewart J, Fleshner N, Cole H, Toi A, Sweet J.

J Urol. 2008 May;179(5):1751-5; discussion 1755. doi: 10.1016/j.juro.2008.01.012. Epub 2008 Mar 17.

PMID:
18343427
14.

Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.

Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.

PMID:
25029122
15.

Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.

Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA.

Am J Clin Pathol. 2004 Oct;122(4):517-23.

16.
17.

Prostate cancer antigen-1 as a potential novel marker for prostate cancer.

Liu BQ, Wu YD, Li PH, Wei JX, Zhang T, Liu RL.

Asian J Androl. 2007 Nov;9(6):821-6.

19.

[The morphogenesis of cancer of the prostate (immunohistochemical research)].

Vorobĭova LR.

Lik Sprava. 1998 May;(3):87-90. Ukrainian.

PMID:
9695575
20.
Items per page

Supplemental Content

Write to the Help Desk